We’re gearing up for the World Vaccine Congress, which is being held in Washington D.C. from April 14th to 17th. Having run for nearly two decades, the conference demonstrates how innovative research can be integrated into Pharma, academia and policy, in order to help deliver vaccines to market.
Daniel Conlon, VP of North American Business Development, and Stefania Di Marco, QP at IRBM’s GMP-compliant adenoviral-based vaccine manufacturing facility ADVENT, will be in attendance. Curious about IRBM and ADVENT’s exceptional services? Get in touch to arrange a meeting.